Blog

In the landscape of medical research, equity, diversity, and inclusivity (EDI) are not merely buzzwords but guiding principles that shape the trajectory of progress. Nowhere is this more apparent than in the realm of gynecologic cancer clinical trials, where the pursuit of equitable healthcare access intersects with the complexities of patient diversity.

Imagine hearing that a loved one — your mother, father, husband, wife, or someone else whom you care immensely about — has been diagnosed with a debilitating disease such as cancer or multiple sclerosis.

There is immense power in listening and learning from the patient perspective. Through meeting patient advocates and hearing their stories, I witness this in my role everyday as Pfizer’s Vice President of Global Patient Advocacy.

For many of us access to care is not something that we struggle with or even give much thought. We may have a great health care insurance or live in a country where you have universal health coverage.

A key component of the many of our efforts as well as our law makers is focused on health care; a problem that has been discussed in just about every circle and corner of society. No one will argue that the need to improve health care is paramount. Children, working poor, minorities, and women are at the top of the list when it comes to needing better access and higher quality of health care. The goal must be to provide equal health care for every man, woman, and child, no matter who they are.

Each of us is involved in some way as a patient at some point in our lives. It is unavoidable. Even if it is for a simple annual checkup or injury. My question to you is how engaged are you with your health care professional (HCP) during your visit and do you ask questions during your visit?